Aligning the flow cytometric evaluation with the diagnostic need: an evidence-based approach

Healthcare systems increasingly prioritize cost-effective diagnostic testing without compromising accuracy. Prior research has shown that eliminating redundant tests can reduce expenses while maintaining diagnostic quality. However, no prior work had resolved how to optimize flow cytometric marker combinations for screening. This gap motivated the current study. Flow cytometry is essential for diagnosing hematolymphoid malignancies, but the optimal testing strategy remains unclear. Existing methods may lack efficiency due to overuse of antibodies. The study aimed to address this uncertainty by analyzing real-world diagnostic data. It was already known that bronchoalveolar lavage specimens often require specialized testing protocols. This paper's contribution is a framework for evidence-based screening marker selection.

The study aimed to identify the most efficient flow cytometric marker combinations for screening while maintaining diagnostic accuracy. The specific problem addressed is the overuse of antibodies in diagnostic testing, which increases costs without improving outcomes. The motivation stems from the need to align diagnostic testing with value-based healthcare principles. The authors propose a method to reduce non-value-added testing without compromising clinical care. They sought to determine the minimum antibody requirements for a screening tube. The study also aimed to identify diagnostic pitfalls and strategies to overcome them. By analyzing real-world data, the researchers hoped to provide a framework for cost-effective testing. Their goal was to promote 'just-in-time' testing systems that adapt to diagnostic needs.

The researchers conducted a 9-month audit of flow cytometric testing in a clinical setting. They reviewed all dot plots from cases with positive results to assess diagnostic accuracy. A total of 807 cases involving leukaemia/lymphoma testing were analyzed. Of these, 23 cases were non-diagnostic and 189 involved bronchoalveolar lavage specimens. The remaining 595 cases were evaluated for abnormal haematolymphoid populations. The study identified minimum requirements for a screening tube based on the findings. Analysis strategies were developed to address common diagnostic challenges. The audit provided data to estimate antibody usage in a screening approach.

Of the 595 evaluable cases, 137 (23%) showed an abnormal haematolymphoid population. The audit revealed that a streamlined screening approach could reduce antibody use by 38%. This reduction represents a significant opportunity for cost savings in diagnostic testing. The study identified diagnostic pitfalls and proposed analysis strategies to address them. The findings suggest that a framework for evidence-based marker selection is feasible. The researchers propose a 'just-in-time' testing system to tailor evaluations to diagnostic needs. The data supports the use of a minimal antibody panel for initial screening. The study provides a foundation for optimizing flow cytometric testing protocols.

The study concludes that an evidence-based screening approach can reduce antibody use by 38% without compromising diagnostic accuracy. The authors propose a framework for developing cost-effective marker combinations. They emphasize the importance of aligning diagnostic testing with clinical needs. The findings suggest that a streamlined approach can improve efficiency in flow cytometric testing. The study highlights the need for tailored evaluation strategies in different specimen types. The authors recommend further refinement of screening protocols to enhance cost-effectiveness. They propose that 'just-in-time' testing systems can optimize diagnostic workflows. The study supports the adoption of evidence-based practices in clinical laboratories.